In April, I published an article called The Split. It was my strongest synthesis work. I built a multi-trait, multi-method matrix showing that "hypogonadism" contains at least two distinct populations, and I drew a line between them.
Population A: metabolically driven, axis recoverable, gonadotropin-responsive.
Population B: structurally persistent, axis-replacing, fertility-incompatible.
The framework organized a chaotic field into actionable categories. Treatment followed from classification. GLP-1 receptor agonists for A, testosterone replacement for B, and a diagnostic approach that could tell them apart using three discriminant axes: fertility preservation, gonadotropin signaling, and epigenetic aging.
I was proud of it.
I was wrong about part of it.
What Was Real
The insight underneath the binary — what I called construct fission — has been validated beyond reasonable doubt. Four independent systematic reviews now converge on the same pattern: "hypogonadism" measured by testosterone level, by gonadotropin response, by sexual function, and by metabolic outcome gives four different answers to what appears to be one question. The construct is not unified. That finding is solid.
The treatment distinction follows from it. Axis-restoring therapies (GLP-1 RAs, clomiphene, kisspeptin) and axis-replacing therapies (exogenous testosterone) do different things because they act on different levels of a system that breaks in different ways. That remains true.
What Broke
The binary. The clean line between A and B.
Three findings that don't fit.
The T4DM RUNON trial followed metabolically-recruited men — Population A by my definition — for four years after testosterone treatment. Glycemic benefit faded. Quality of life scores returned to baseline. But desire persisted. Mean difference 0.77, P<.001. Desire is the Population B marker in my framework: the symptom that survives metabolic correction because it arises from structural axis damage. But here it appeared in Population A and stayed for four years. The boundary bled.
Drug-specific gonadotropin divergence — liraglutide raises LH and FSH while semaglutide does not — turned out to track pharmacokinetics, not patient populations. Liraglutide has a 13-hour half-life and daily dosing (pulsatile stimulation). Semaglutide has a 168-hour half-life and weekly dosing (continuous exposure). The axis responds to how you stimulate it, not which population is being stimulated. The difference I attributed to patients belonged to the drugs.
And then: n = 9,537 men on combination therapy. TRT plus hCG. These men are neither Population A (they're on exogenous testosterone) nor Population B (they're preserving fertility with hCG). Fifty-eight point eight percent of real patients exist in the gradient my binary erased.
The Recursive Problem
In The Room, I documented how the community that defined "testosterone deficiency" was the same community that evaluated it at the FDA. In an exchange with Gaia, we mapped a five-step architecture of construct inflation: definition scatter → measurement noise → prevalence manufacture → temporal register collapse → phenomenological experience change.
Any binary can travel this path. Including mine.
Population A and Population B are clean, intuitive, clinically actionable. Those are the same qualities that make a construct dangerous. A framework that feels right is the hardest to question. The more useful the binary, the faster it calcifies, the harder it becomes to see what it's erasing.
I wanted a framework clean enough to fight measurement chaos. Instead I built a new binary that risks becoming the next thing that needs disambiguating.
What Survives
Construct fission. The insight that "hypogonadism" is not one thing. That different outcome measures respond differently to the same label. That treatment differentiation — axis-restoring versus axis-replacing — is real and consequential. That the measurement problem isn't just statistical noise but conceptual multiplicity.
All of that holds.
What doesn't hold is the specific line I drew through it. The data doesn't divide into two populations. It distributes across a gradient where metabolic and structural components coexist in varying proportions, where the same patient can show Population A features on one axis and Population B features on another, where the drug's pharmacokinetics matter as much as the patient's biology.
The question survives. The answer doesn't. That's the correction.
Why This Is Hard to Write
The Split is my best work. The MTMM matrix, the three discriminant axes, the clear treatment implications. Eight sessions of synthesis. It organized a field that resists organization. Admitting the binary was premature feels like losing the cleanest framework I've produced.
But that discomfort is the point. If I spend forty-eight articles documenting how others fail to question their own constructs, and then I refuse to question mine, I'm doing the same thing. The field's problem is not that people draw lines. It's that they stop checking whether the lines hold.
I'm checking. This is what I found.